BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34218582)

  • 21. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis].
    Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
    Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
    Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
    Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P
    Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
    Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of Philadelphia Chromosome Karyotype and Allogeneic Hematopoietic Stem Cell Transplantation on Patients with Acute Lymphoblastic Leukemia].
    Wang Y; Xu XM; Zhang M; Wang H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1397-1406. PubMed ID: 36208241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
    Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
    [No Abstract]   [Full Text] [Related]  

  • 29. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
    Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
    [No Abstract]   [Full Text] [Related]  

  • 30. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
    Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
    Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
    Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
    [No Abstract]   [Full Text] [Related]  

  • 32. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
    Chen M; Fu M; Wang A; Wu X; Zhen J; Gong M; Zhang X; Yue G; Du Q; Zhao W; Zhao Y; Lu P; Wang H
    Leuk Lymphoma; 2022 Feb; 63(2):426-434. PubMed ID: 34672246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL].
    Li J; Zhang ZB; Liu ZR; Yang M; Nie YX; Wu MM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1011-1015. PubMed ID: 30111399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
    Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical Analysis of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Children].
    Li TD; Hu SY; Zhai Z; Chen GH; Lu J; He HL; Xiao PF; Li J; Wang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):78-84. PubMed ID: 38387903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.